This application requests supplemental funding to the TrialNet Coordinating Center and the TrialNet overall to complete existing studies, launch new studies and continue operations. It is submitted in response to RFA-DK-19-506, Limited Competition: Competitive Supplement to the Coordinating Center for Type 1 Diabetes TrialNet. As a competing revision application, this request does not change the scope of work, but provides funds to cover an expansion of the TNCC's approved scope of work and provide funds to cover additional costs to accomplish tasks that need to be continued or expanded. It is intended to provide additional resources to build on TrialNet prior study results through the design and conduct of new intervention studies in individuals at early pre-clinical stages of T1D and in individuals with new-onset T1D. In addition, this supplement will be used to consider and design future trials. In year 3, this funding will support TrialNet's ongoing screening efforts, prevention studies and new-onset studies, and the development and implementation of new TrialNet prevention and new-onset studies. Funds provided by this supplement will fund the TrialNet Chair and TrialNet central laboratories and support units.
The goal of Type 1 Diabetes TrialNet is the prevention of type 1 diabetes in individuals at- risk for its development. This application is submitted in response to RFA-DK-19-506, Limited Competition: Competitive Supplement to the Coordinating Center for Type 1 Diabetes TrialNet. As a competing revision application, this request does not change the scope of work, but provides funds to cover an expansion of the TNCC?s approved scope of work and provide funds to cover additional costs to accomplish tasks that need to be continued or expanded. It is intended to provide additional resources to build on TrialNet prior study results through the design and conduct of new intervention studies in individuals at early pre-clinical stages of T1D and in individuals with new-onset T1D. This supplement will be used to launch and conduct new trials, to complete existing trials in follow-up, and to consider and design future trials. In year 3, this funding will additionally support TrialNet's ongoing screening efforts, prevention studies and new- onset studies, and will support the development and implementation of new TrialNet prevention and new-onset studies.
